Corrigendum to ‘Oral Azvudine for hospitalised patients with COVID-19 and pre-existing conditions: a retrospective cohort study.’ [EClinicalMedicine 59 (2023) 101981]

Corrigendum to ‘Oral Azvudine for hospitalised patients with COVID-19 and pre-existing conditions: a retrospective cohort study.’ [EClinicalMedicine 59 (2023) 101981]

Bibliographic Details
Main Authors:	Yuming Sun, Liping Jin, Yating Dian, Minxue Shen, Furong Zeng, Xiang Chen, Guangtong Deng
Format:	Article
Language:	English
Published:	Elsevier 2023-08-01
Series:	EClinicalMedicine
Online Access:	http://www.sciencedirect.com/science/article/pii/S2589537023002870

Similar Items

Oral Azvudine for hospitalised patients with COVID-19 and pre-existing conditions: a retrospective cohort studyResearch in context
by: Yuming Sun, et al.
Published: (2023-05-01)

Response to the letter by Prof Jonathan Deeks to the Lancet EClinicalMedicine editor
by: Leber, W, et al.
Published: (2021)

Lactate dehydrogenase predicts disease progression outcome in COVID-19 patients treated with Azvudine
by: Manyun Mao, et al.
Published: (2023-10-01)

Corrigendum to “Treatment-related adverse events associated with HER2-Targeted antibody-drug conjugates in clinical trials: a systematic review and meta-analysis” [EClinicalMedicine 55 (2022) 101795]
by: Zhiwen Fu, et al.
Published: (2023-04-01)

Association of eosinopenia with worsening prognosis in hospitalized Azvudine-treated COVID-19 patients: a retrospective cohort study
by: Xiaomin Wang, et al.
Published: (2023-12-01)

Corrigendum to “Multidimensional poverty is associated with dementia among adults in Afghanistan” [eClinicalMedicine 58(2023) 101906]
by: Jean-Francois Trani, et al.
Published: (2024-08-01)

Thank you to eClinical Medicine’s clinical and statistical peer reviewers in 2023
Published: (2024-01-01)

Corrigendum to—“Food deprivation among adults in India: an analysis of specific food-categories, 2016–2021” [eClinical medicine 66(2023) 102313]
by: Anoop Jain, et al.
Published: (2024-03-01)

Clinical characteristics and risk factors for ZF2001 fully vaccinated inpatients with COVID-19: A retrospective cohort study
by: Liping Jin, et al.
Published: (2024-12-01)

Efficacy and safety of tebentafusp in patients with metastatic uveal melanoma: A systematic review and meta-analysis
by: Yating Dian, et al.
Published: (2024-12-01)

eClinic: increasing use of telehealth as a risk reduction strategy during the covid-19 pandemic
by: Aaron M Williams, et al.
Published: (2020-12-01)

Immunophenotyping characteristics and outcome of COVID‐19 patients: peripheral blood CD8+T cell as a prognostic biomarker for patients with Nirmatrelvir
by: Yuming Sun, et al.
Published: (2023-09-01)

Real-world effectiveness of azvudine versus nirmatrelvir-ritonavir in hospitalized patients with COVID-19 and pre-existing diabetes
by: Guanyue Su, et al.
Published: (2025-02-01)

Azvudine for the Treatment of COVID‐19 in Pre‐Existing Cardiovascular Diseases: A Single‐Center, Real‐World Experience
by: Liu Wu, et al.
Published: (2024-06-01)

Azvudine efficacy in reducing mortality in COVID-19 patients
by: Zhen Zhong, et al.
Published: (2024-12-01)

Immune checkpoint inhibitors in cancer patients with autoimmune disease: Safety and efficacy
by: Jiayuan Le, et al.
Published: (2025-12-01)

A multicenter, real-world cohort study: effectiveness and safety of Azvudine in hospitalized COVID-19 patients with pre-existing diabetes
by: Yongjian Zhou, et al.
Published: (2025-02-01)

2023: Núm. 59 - nov
by: Observatori de Bioètica i Dret
Published: (2023-10-01)

Comparison of Azvudine and Nirmatrelvir/Ritonavir and Combined Use in Patients with COVID-19
by: Hu CY, et al.
Published: (2023-12-01)

Azvudine versus paxlovid for oral treatment of COVID-19 in Chinese patients
by: Peng Su, et al.
Published: (2024-01-01)

The first Chinese oral anti-COVID-19 drug Azvudine launched
by: Bin Yu, et al.
Published: (2022-11-01)

Response to comment on: “Efficacy and safety of tebentafusp in patients with metastatic uveal melanoma: A systematic review and meta-analysis”
by: Danyao Chen, et al.
Published: (2024-12-01)

Correction: Using Participatory Design Methodologies to Co-Design and Culturally Adapt the Spanish Version of the Mental Health eClinic: Qualitative Study
by: Laura Ospina-Pinillos, et al.
Published: (2022-03-01)

Selectively T cell phosphorylation activation of azvudine in the thymus tissue with immune protection effect
by: Ning Sheng, et al.
Published: (2024-07-01)

Comparison of the therapeutic effect of Paxlovid and Azvudine in the treatment of COVID-19: A retrospective study
by: Wei Yang, et al.
Published: (2024-12-01)

Effectiveness of nirmatrelvir-ritonavir versus azvudine for adult inpatients with severe or critical COVID-19
by: Junjun Chen, et al.
Published: (2024-07-01)

Azvudine reduces the in-hospital mortality of COVID-19 patients: A retrospective cohort study
by: Kaican Zong, et al.
Published: (2023-11-01)

Efficacy and safety of azvudine in patients with COVID-19: A systematic review and meta-analysis
by: Zhaoyan Chen, et al.
Published: (2023-09-01)

Elevated INR in a COVID-19 patient after concomitant administration of azvudine and anticoagulants
by: Xi Zhang, et al.
Published: (2023-05-01)

Front Matter Vol.59 No.1 [3/2023]
by: Folia Medica Indonesiana
Published: (2023-03-01)

Back Matter Vol.59 No.1 [3/2023]
by: Folia Medica Indonesiana
Published: (2023-03-01)

Immunophenotyping characteristics and clinical outcome of COVID-19 patients treated with azvudine during the Omicron surge
by: Meihua Qiu, et al.
Published: (2024-11-01)

Efficacy and Safety of Azvudine in Patients With COVID‐19 in China: A Meta‐Analysis of Observational Studies
by: Tao Dong, et al.
Published: (2024-07-01)

Effectiveness of azvudine in reducing mortality of COVID-19 patients: a systematic review and meta-analysis
by: Yaqi Wang, et al.
Published: (2024-02-01)

Efficacy of Nirmatrelvir-Ritonavir versus Azvudine for COVID-19 Treatment in Tibet: A Retrospective Study
by: Zhao X, et al.
Published: (2023-09-01)

Efficacy of azvudine plus dexamethasone in severe hospitalized patients with Omicron infection: a prospective multicenter study
by: Meng-Lan Zhang, et al.
Published: (2024-11-01)

Effectiveness and safety of azvudine in older adults with mild and moderate COVID-19: a retrospective observational study
by: Zhiguo Zhou, et al.
Published: (2024-01-01)

Ferroptosis: mechanisms and therapeutic targets
by: Qian Zhou, et al.
Published: (2024-12-01)

Molecular landmarks of tumor disulfidptosis across cancer types to promote disulfidptosis-target therapy
by: Deze Zhao, et al.
Published: (2023-12-01)

Systematic evaluation of therapeutic effectiveness of Azvudine in treating COVID-19 hospitalized patients: a retrospective cohort study
by: Yingkai Xu, et al.
Published: (2024-11-01)